Please select the eligibility criteria that correspond to the clinical trial below.
Title: Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis: Double-blind Controlled Clinical Trial
Brief Summary: The adjunctive use of systemically administered antibiotics has been shown to provide a better clinical outcome, particularly in terms of probing depth (PD) reduction and attachment-level gain than SRP in subjects with Aggressive Periodontitis.

The overall objective of this study is to evaluate the clinical and microbiological efficacy of moxifloxacin as an adjunct to scaling and root planing versus scaling and root planing over placebo in the treatment of aggressive periodontitis.


Options:
A: Inclusion Criteria:

* under 30 years old and systemically healthy, with at least 20 teeth present. Be willing to participate in the study which is corroborated by signing the informed consent form.

Commit to attend post-therapeutic controls and stop drinking alcohol during the time of ingestion of antibiotics.

Exclusion Criteria:

* Subjects in whom are contraindicated or with hypersensitivity to quinolones - Subjects who have undergone periodontal, surgical or mechanical antibiotic therapy six months before the start of the study according to interrogation.

Women in pregnancy or lactation, corroborated with previous medical history and medical consultation.
B: Inclusion Criteria:

* \> 20 teeth
* \> 5% sites (approx. 8 sites) with pocket depth \> 4 mm and / or 5% sites with attachment level \> 4 mm and mean AL \< 4.5 mm and mean PD \< 3.9 mm (not including tooth brush abrasions).

Exclusion Criteria:

* \> 50% of sites with pocket depth or attachment level \> 4 mm
* Pregnancy or nursing
* Periodontal or antibiotic therapy in the previous 6 months
* Any systemic condition which might influence the course of periodontal disease or treatment (e.g. diabetes, AIDS)
* Any systemic condition which requires antibiotic coverage for routine periodontal procedures (e.g. heart conditions, joint replacements etc.)
* Liver disease
* Any known allergy to amoxicillin, metronidazole or doxycycline
* Lactose intolerance
C: Inclusion Criteria:

* Subjects must be 20 years of age or older
* Have at least 18 natural teeth
* Four or more clinical attachment level(CAL) ≥ 3mm
* Four or more periodontal pockets with a probing depth (PD) ≥ 4mm
* Have Bleeding on probing
* Provide informed consent and willingness to cooperate with the study protocol

Exclusion Criteria:

* Forbidden History of Panax Notoginseng and Rehmanniae Radix Preparata
* Hypersensitivity of Doxycycline
* Hypersensitivity of Zea mays L. extract
* Critical diseases such as HIV previous three years
* Patients with mental retardation and dementia
* Systemic diseases such as diabetes and hypertension
* Patients who take Anticoagulants or Antiplatelet Agents
* Patients who have malignant tumor
* Smoker
* Continually use for 2weeks of phenytoin, calcium channel blocker, cyclosporin, coumarin, nonsteroidal anti-inflammatory drugs and aspirin use in the previous one month
* Patients who need malignant tumor
* Patients who received periodontal treatment within the last 6 months
* Pregnant or lactating females
D: Inclusion Criteria:

* Females and males with advanced periodontal disease referred between November 2007 and January 2009.
* No diseases known to be associated with periodontal diseases, i.e. diabetes mellitus, rheumatoid arthritis, pregnancies.
* No continuous medication known to affect the severity or progression of periodontal diseases.
* No previous systematic periodontal treatment.
* More than 5 pockets 5mm \< PPD \< 9 mm after a 3 month hygiene phase - i.e. before inclusion into study.
* Oral hygiene; \< 5% of surfaces with plaque at inclusion time.
* Signing an informed consent.

Exclusion criteria:

* diseases known to be associated with periodontal diseases, i.e. diabetes mellitus, rheumatoid arthritis.
* pregnancy
* continuous medication known to affect the clinical expression of periodontal diseases
* subgingival microbiological diagnosis which reveals bacteria with reduced/no sensitivity to metronidazole

Answer: A